Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

The Role of Cytokines in the Fibrotic Responses in Crohn's Disease.

Curciarello R, Docena GH, MacDonald TT.

Front Med (Lausanne). 2017 Aug 7;4:126. doi: 10.3389/fmed.2017.00126. eCollection 2017. Review.

2.

Association of Ribonuclease T2 Gene Polymorphisms With Decreased Expression and Clinical Characteristics of Severity in Crohn's Disease.

Gonsky R, Fleshner P, Deem RL, Biener-Ramanujan E, Li D, Potdar AA, Bilsborough J, Yang S, McGovern DPB, Targan SR.

Gastroenterology. 2017 Jul;153(1):219-232. doi: 10.1053/j.gastro.2017.04.002. Epub 2017 Apr 9.

PMID:
28400196
3.

Directed evolution of a soluble human DR3 receptor for the inhibition of TL1A induced cytokine secretion.

Levin I, Zaretsky M, Aharoni A.

PLoS One. 2017 Mar 9;12(3):e0173460. doi: 10.1371/journal.pone.0173460. eCollection 2017.

4.

TNF superfamily cytokines in the promotion of Th9 differentiation and immunopathology.

Meylan F, Siegel RM.

Semin Immunopathol. 2017 Jan;39(1):21-28. doi: 10.1007/s00281-016-0612-y. Epub 2016 Nov 28. Review.

PMID:
27896636
5.

Death Receptor 3 Promotes Chemokine-Directed Leukocyte Recruitment in Acute Resolving Inflammation and Is Essential for Pathological Development of Mesothelial Fibrosis in Chronic Disease.

Perks WV, Singh RK, Jones GW, Twohig JP, Williams AS, Humphreys IR, Taylor PR, Jones SA, Wang ECY.

Am J Pathol. 2016 Nov;186(11):2813-2823. doi: 10.1016/j.ajpath.2016.07.021. Epub 2016 Sep 21.

6.

Cytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBD.

Jacob N, Targan SR, Shih DQ.

United European Gastroenterol J. 2016 Aug;4(4):531-40. doi: 10.1177/2050640616649356. Epub 2016 May 10. Review.

7.

Characterization of death receptor 3-dependent aortic changes during inflammatory arthritis.

Williams JO, Wang EC, Lang D, Williams AS.

Pharmacol Res Perspect. 2016 Jun 10;4(4):e00240. eCollection 2016 Aug.

8.

A Novel Role for TL1A/DR3 in Protection against Intestinal Injury and Infection.

Jia LG, Bamias G, Arseneau KO, Burkly LC, Wang EC, Gruszka D, Pizarro TT, Cominelli F.

J Immunol. 2016 Jul 1;197(1):377-86. doi: 10.4049/jimmunol.1502466. Epub 2016 May 27.

9.

The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

Ward-Kavanagh LK, Lin WW, Šedý JR, Ware CF.

Immunity. 2016 May 17;44(5):1005-19. doi: 10.1016/j.immuni.2016.04.019. Review.

10.

Differential Levels of Tl1a Affect the Expansion and Function of Regulatory T Cells in Modulating Murine Colitis.

Sidhu-Varma M, Shih DQ, Targan SR.

Inflamm Bowel Dis. 2016 Mar;22(3):548-59. doi: 10.1097/MIB.0000000000000653.

11.

Genetically engineered mouse models for studying inflammatory bowel disease.

Mizoguchi A, Takeuchi T, Himuro H, Okada T, Mizoguchi E.

J Pathol. 2016 Jan;238(2):205-19. doi: 10.1002/path.4640. Epub 2015 Nov 14. Review.

12.

The TNF-family cytokine TL1A: from lymphocyte costimulator to disease co-conspirator.

Richard AC, Ferdinand JR, Meylan F, Hayes ET, Gabay O, Siegel RM.

J Leukoc Biol. 2015 Sep;98(3):333-45. doi: 10.1189/jlb.3RI0315-095R. Epub 2015 Jul 17. Review.

13.

Divergent behavior of mucosal memory T cells.

Pham OH, McSorley SJ.

Mucosal Immunol. 2015 Jul;8(4):731-4. doi: 10.1038/mi.2015.52. Epub 2015 Jun 10.

14.

Human group3 innate lymphoid cells express DR3 and respond to TL1A with enhanced IL-22 production and IL-2-dependent proliferation.

Ahn YO, Weeres MA, Neulen ML, Choi J, Kang SH, Heo DS, Bergerson R, Blazar BR, Miller JS, Verneris MR.

Eur J Immunol. 2015 Aug;45(8):2335-42. doi: 10.1002/eji.201445213. Epub 2015 Jun 22.

15.

Experimental Models of Inflammatory Bowel Diseases.

Kiesler P, Fuss IJ, Strober W.

Cell Mol Gastroenterol Hepatol. 2015 Mar 1;1(2):154-170.

16.

The TNF-family ligand TL1A and its receptor DR3 promote T cell-mediated allergic immunopathology by enhancing differentiation and pathogenicity of IL-9-producing T cells.

Richard AC, Tan C, Hawley ET, Gomez-Rodriguez J, Goswami R, Yang XP, Cruz AC, Penumetcha P, Hayes ET, Pelletier M, Gabay O, Walsh M, Ferdinand JR, Keane-Myers A, Choi Y, O'Shea JJ, Al-Shamkhani A, Kaplan MH, Gery I, Siegel RM, Meylan F.

J Immunol. 2015 Apr 15;194(8):3567-82. doi: 10.4049/jimmunol.1401220. Epub 2015 Mar 18. Erratum in: J Immunol. 2015 Dec 15;195(12):5839-40.

17.

A major population of mucosal memory CD4+ T cells, coexpressing IL-18Rα and DR3, display innate lymphocyte functionality.

Holmkvist P, Roepstorff K, Uronen-Hansson H, Sandén C, Gudjonsson S, Patschan O, Grip O, Marsal J, Schmidtchen A, Hornum L, Erjefält JS, Håkansson K, Agace WW.

Mucosal Immunol. 2015 May;8(3):545-58. doi: 10.1038/mi.2014.87. Epub 2014 Oct 1.

18.

Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease.

Ślebioda TJ, Kmieć Z.

Mediators Inflamm. 2014;2014:325129. doi: 10.1155/2014/325129. Epub 2014 Jun 17. Review.

19.

Regulation of early cartilage destruction in inflammatory arthritis by death receptor 3.

Wang EC, Newton Z, Hayward OA, Clark SR, Collins F, Perks WV, Singh RK, Twohig JP, Williams AS.

Arthritis Rheumatol. 2014 Oct;66(10):2762-72. doi: 10.1002/art.38770.

20.

Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis.

Shih DQ, Zheng L, Zhang X, Zhang H, Kanazawa Y, Ichikawa R, Wallace KL, Chen J, Pothoulakis C, Koon HW, Targan SR.

Mucosal Immunol. 2014 Nov;7(6):1492-503. doi: 10.1038/mi.2014.37. Epub 2014 May 21.

Supplemental Content

Support Center